BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 34255389)

  • 21. Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma-pheochromocytoma syndrome.
    Greenberg SE; Jacobs MF; Wachtel H; Anson A; Buchmann L; Cohen DL; Bonanni M; Bennett B; Naumer A; Schaefer AM; Kohlmann W; Nathanson KL; Else T; Fishbein L
    Genet Med; 2020 Dec; 22(12):2101-2107. PubMed ID: 32741965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
    Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice.
    Saie C; Buffet A; Abeillon J; Drui D; Leboulleux S; Bertherat J; Zenaty D; Storey C; Borson-Chazot F; Burnichon N; Vincent M; Favier J; Baudin E; Giraud S; Gimenez-Roqueplo AP; Amar L; Lussey-Lepoutre C
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1301-e1315. PubMed ID: 33247927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma.
    Perez K; Jacene H; Hornick JL; Ma C; Vaz N; Brais LK; Alexander H; Baddoo W; Astone K; Esplin ED; Garcia J; Halperin DM; Kulke MH; Chan JA
    Endocr Relat Cancer; 2022 Sep; 29(9):533-544. PubMed ID: 35731023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paraganglioma and other tumour detection rates in individuals with SDHx pathogenic variants by age of diagnosis and after the age of 50.
    Greenberg SE; Holman R; Kohlmann W; Buchmann L; Naumer A
    Clin Endocrinol (Oxf); 2021 Sep; 95(3):447-452. PubMed ID: 34255389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma.
    Timmers HJ; Gimenez-Roqueplo AP; Mannelli M; Pacak K
    Endocr Relat Cancer; 2009 Jun; 16(2):391-400. PubMed ID: 19190077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DIAGNOSIS of ENDOCRINE DISEASE: SDHx mutations: beyond pheochromocytomas and paragangliomas.
    Mannelli M; Canu L; Ercolino T; Rapizzi E; Martinelli S; Parenti G; De Filpo G; Nesi G
    Eur J Endocrinol; 2018 Jan; 178(1):R11-R17. PubMed ID: 28924001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: Beyond phaeochromocytoma and paraganglioma.
    MacFarlane J; Seong KC; Bisambar C; Madhu B; Allinson K; Marker A; Warren A; Park SM; Giger O; Challis BG; Maher ER; Casey RT
    Clin Endocrinol (Oxf); 2020 Nov; 93(5):528-538. PubMed ID: 32686200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
    Vicha A; Taieb D; Pacak K
    Endocr Relat Cancer; 2014 Jun; 21(3):R261-77. PubMed ID: 24500761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma.
    Buffet A; Burnichon N; Favier J; Gimenez-Roqueplo AP
    Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101416. PubMed ID: 32295730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pathologist contribution in the diagnosis of hereditary predisposition to paranganglioma and pheochromocytoma].
    Broudin C; Favier J; Verkarre V; Méatchi T
    Ann Pathol; 2020 Apr; 40(2):134-141. PubMed ID: 32146049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hereditary pheochromocytoma and paraganglioma: screening and follow-up strategies in asymptomatic mutation carriers].
    Vermalle M; Tabarin A; Castinetti F
    Ann Endocrinol (Paris); 2018 Sep; 79 Suppl 1():S10-S21. PubMed ID: 30213301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
    Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
    Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.